FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

James Atkins

Research Profile

Procedures

Concepts & Ideas

Chemicals & Drugs

Disorders

Co-author Network

Publications

TOP 3
Edward Romond; Sandra M Swain; Elizabeth Tan-Chiu; Greg Yothers; John L Zapas; Ping Zheng; James N Atkins; Catherine A Azar; David D Biggs; Adam Brufsky; Michael S Ewer; Louis Fehrenbacher; Patrick J Flynn; Charles E Geyer; Howard M Gross; Jong-Hyeon Jeong; Eleftherios P Mamounas; Jonathan Polikoff; Priya Rastogi; Vikas Rathi; Norman Wolmark
Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer.
Harry D Bear; Adam M Brufsky; Joseph P Costantino; Louis Fehrenbacher; Rakesh Gaur; Charles E Geyer; Howard M Gross; Eleftherios P Mamounas; Richard G Margolese; Rita S Mehta; Priya Rastogi; Andre Robidoux; Francis M Senecal; Sandra M Swain; Gong Tang; Paul T Adams; James N Atkins; Luis Baez-Diaz; James A Young; Norman Wolmark
Bevacizumab added to neoadjuvant chemotherapy for breast cancer.
Sandra M Swain; Jong-Hyeon Jeong; Charles E Geyer; Joseph P Costantino; Eduardo R Pajon; Louis Fehrenbacher; James N Atkins; Jonathan Polikoff; Victor Vogel; John K Erban; Priya Rastogi; Robert B Livingston; Edith A Perez; Eleftherios P Mamounas; Stephanie R Land; Patricia Anne Ganz; Norman Wolmark
Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of James Atkins (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2012: Edward Romond; Sandra M Swain; Elizabeth Tan-Chiu; Greg Yothers; John L Zapas; Ping Zheng; James N Atkins; Catherine A Azar; David D Biggs; Adam Brufsky; Michael S Ewer; Louis Fehrenbacher; Patrick J Flynn; Charles E Geyer; Howard M Gross; Jong-Hyeon Jeong; Eleftherios P Mamounas; Jonathan Polikoff; Priya Rastogi; Vikas Rathi; Norman Wolmark
Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2012;30(31):3792-9.
2012: Harry D Bear; Adam M Brufsky; Joseph P Costantino; Louis Fehrenbacher; Rakesh Gaur; Charles E Geyer; Howard M Gross; Eleftherios P Mamounas; Richard G Margolese; Rita S Mehta; Priya Rastogi; Andre Robidoux; Francis M Senecal; Sandra M Swain; Gong Tang; Paul T Adams; James N Atkins; Luis Baez-Diaz; James A Young; Norman Wolmark
Bevacizumab added to neoadjuvant chemotherapy for breast cancer.
The New England journal of medicine 2012;366(4):310-20.
2010: Sandra M Swain; Jong-Hyeon Jeong; Charles E Geyer; Joseph P Costantino; Eduardo R Pajon; Louis Fehrenbacher; James N Atkins; Jonathan Polikoff; Victor Vogel; John K Erban; Priya Rastogi; Robert B Livingston; Edith A Perez; Eleftherios P Mamounas; Stephanie R Land; Patricia Anne Ganz; Norman Wolmark
Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer.
The New England journal of medicine 2010;362(22):2053-65.
2009: Carmen J Allegra; Greg Yothers; Michael J O'Connell; Saima Sharif; Linda H Colangelo; Samia H Lopa; Nicholas J Petrelli; Richard M Goldberg; James N Atkins; Thomas E Seay; Louis Fehrenbacher; Seamus O'Reilly; Luis Chu; Catherine A Azar; Norman Wolmark
Initial safety report of NSABP C-08: A randomized phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II or III colon cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(20):3385-90.
2007: Wallace Akerley; Jason McCoy; Paul J Hesketh; J Wendall Goodwin; James Bearden; James N Atkins; Kari Chansky; John J Crowley; David R Gandara
Gemcitabine and irinotecan for patients with untreated extensive stage small cell lung cancer: SWOG 0119.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2007;2(6):526-30.
2007: J Philip Kuebler; H Samuel Wieand; Michael J O'Connell; Roy E Smith; Linda H Colangelo; Greg Yothers; Nicholas J Petrelli; Michael P Findlay; Thomas E Seay; James N Atkins; John L Zapas; J Wendall Goodwin; Louis Fehrenbacher; Ramesh K Ramanathan; BA Conley; Patrick J Flynn; Gamini Soori; Lauren K Colman; Edward A Levine; Keith S Lanier; Norman Wolmark
Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(16):2198-204.
2007: Everett E Vokes; James E Herndon; Michael J Kelley; M Giulia Cicchetti; Nithya Ramnath; Harvey Neill; James N Atkins; Dorothy M Watson; Wallace Akerley; Mark R Green
Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III Non-small-cell lung cancer: Cancer and Leukemia Group B.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(13):1698-704.
2007: Wolfram E Samlowski; James Moon; J Philip Kuebler; Craig Nichols; David R Gandara; Howard Ozer; Stephen K Williamson; James N Atkins; David E Schuller; John F Ensley
Evaluation of the combination of docetaxel/carboplatin in patients with metastatic or recurrent squamous cell carcinoma of the head and neck (SCCHN): a Southwest Oncology Group Phase II study.
Cancer investigation 2007;25(3):182-8.
2006: Primo Lara; Kari Chansky; Angela M Davies; Wilbur A Franklin; Paul H Gumerlock; Perry P Guaglianone; James N Atkins; Nichole Farneth; Philip C Mack; John J Crowley; David R Gandara
Bortezomib (PS-341) in relapsed or refractory extensive stage small cell lung cancer: a Southwest Oncology Group phase II trial (S0327).
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2006;1(9):996-1001.
2006: Paul J Hesketh; Jason McCoy; Frank R Dunphy; James Bearden; Geoffrey R Weiss; Jeffrey K Giguere; James N Atkins; Shaker R Dakhil; Karen Kelly; John J Crowley; David R Gandara
Phase II trial of paclitaxel, carboplatin, and topotecan with G-CSF support in previously untreated patients with extensive stage small cell lung cancer: Southwest Oncology Group 9914.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2006;1(9):991-5.
2006: Antonius A Miller; Doug Case; James N Atkins; Jeffrey K Giguere; James Bearden
Phase II study of carboplatin, irinotecan, and thalidomide in patients with advanced non-small cell lung cancer.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2006;1(8):832-6.
2006: Steven R Smalley; Jacqueline K Benedetti; Stephen K Williamson; John M Robertson; Norman C. Estes; Tracy Maher; Bernard Fisher; tyvin rich; James A Martenson; John W Kugler; Al B Benson; Daniel G Haller; Robert J Mayer; James N Atkins; Christine Cripps; John Pedersen; Phillip O Periman; Michael S Tanaka; Cynthia G Leichman; John S Macdonald
Phase III trial of fluorouracil-based chemotherapy regimens plus radiotherapy in postoperative adjuvant rectal cancer: GI INT 0144.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(22):3542-7.
2006: Karen M Mustian; Jennifer J Griggs; Gary R Morrow; Anne McTiernan; Joseph A Roscoe; Christopher W Bole; James N Atkins; Brian F Issell
Exercise and side effects among 749 patients during and after treatment for cancer: a University of Rochester Cancer Center Community Clinical Oncology Program Study.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 2006;14(7):732-41.
2006: Victor Vogel; Joseph P Costantino; D Lawrence Wickerham; Walter M Cronin; Reena S Cecchini; James N Atkins; Therese B Bevers; Louis Fehrenbacher; Eduardo R Pajon; James L Wade Iii; Andre Robidoux; Richard G Margolese; Joan James; Scott M Lippman; Carolyn D Runowicz; Patricia Anne Ganz; Steven E Reis; Worta McCaskill-Stevens; Leslie G Ford; V Craig Jordan; Norman Wolmark
Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial.
JAMA : the journal of the American Medical Association 2006;295(23):2727-41.
2006: Stephen K Williamson; Sheryl A McCoy; David R Gandara; Shaker R Dakhil; Kathleen J Yost; Jorge C Paradelo; James N Atkins; Charles D Blanke; James L Abbruzzese
Phase II trial of gemcitabine plus irinotecan in patients with esophageal cancer: a Southwest Oncology Group (SWOG) trial.
American journal of clinical oncology 2006;29(2):116-22.
2005: Bernard Fisher; Joseph P Costantino; D Lawrence Wickerham; Reena S Cecchini; Walter M Cronin; Andre Robidoux; Therese B Bevers; Maureen T Kavanah; James N Atkins; Richard G Margolese; Carolyn D Runowicz; Joan M James; Leslie G Ford; Norman Wolmark
Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study.
Journal of the National Cancer Institute 2005;97(22):1652-62.
2005: Jennifer S Yates; Karen M Mustian; Gary R Morrow; Leslie J Gillies; Devi Padmanaban; James N Atkins; Brian F Issell; Jeffrey J Kirshner; Lauren K Colman
Prevalence of complementary and alternative medicine use in cancer patients during treatment.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 2005;13(10):806-11.
2005: James N Atkins; Samuel A Jacobs; H Samuel Wieand; Roy E Smith; William J John; Linda H Colangelo; Victor Vogel; J Philip Kuebler; Terrence P Cescon; Barbara J Miller; Charles E Geyer; Norman Wolmark
Pemetrexed/oxaliplatin for first-line treatment of patients with advanced colorectal cancer: a phase II trial of the National Surgical Adjuvant Breast and Bowel Project Foundation Research Program.
Clinical colorectal cancer 2005;5(3):181-7.
2005: A. William Blackstock; Jeffrey A. Bogart; Charles Matthews; James Lovato; Thomas P McCoy; Kim Livengood; Coty Ho; Douglas White; James N Atkins; Antonius A Miller
Split-course versus continuous thoracic radiation therapy for limited-stage small-cell lung cancer: final report of a randomized phase III trial.
Clinical lung cancer 2005;6(5):287-92.
2003: Joseph A Roscoe; Gary R Morrow; Jane T Hickok; Peter Bushunow; H Irving Pierce; Patrick J Flynn; Jeffrey J Kirshner; Dennis F Moore; James N Atkins
The efficacy of acupressure and acustimulation wrist bands for the relief of chemotherapy-induced nausea and vomiting. A University of Rochester Cancer Center Community Clinical Oncology Program multicenter study.
Journal of pain and symptom management 2003;26(2):731-42.
2003: Ian M Thompson; Phyllis J Goodman; Catherine M Tangen; M Scott Lucia; Gary J Miller; Leslie G Ford; Michael M Lieber; R. Duane Duane Cespedes; James N Atkins; Scott M Lippman; Susie M Carlin; Anne Ryan; Connie M Szczepanek; John J Crowley; Charles A Coltman
The influence of finasteride on the development of prostate cancer.
The New England journal of medicine 2003;349(3):215-24.
2003: Jane T Hickok; Joseph A Roscoe; Gary R Morrow; David K King; James N Atkins; Tom R Fitch
Nausea and emesis remain significant problems of chemotherapy despite prophylaxis with 5-hydroxytryptamine-3 antiemetics: a University of Rochester James P. Wilmot Cancer Center Community Clinical Oncology Program Study of 360 cancer patients treated in the community.
Cancer 2003;97(11):2880-6.
2002: Darlene J Johnson; Charles B Scott; James E Marks; Thomas E Seay; James N Atkins; Lawrence B Berk; Raul T Meoz; James A Wheeler
Assessment of quality of life and oral function of patients participating in a phase II study of radioprotection of oral and pharyngeal mucosa by the prostaglandin E(1) analog misoprostol (RTOG 96-07).
International journal of radiation oncology, biology, physics 2002;54(5):1455-9.
2001: Bernard Fisher; Steve Anderson; Elizabeth Tan-Chiu; Norman Wolmark; D Lawrence Wickerham; Edwin R Fisher; NV Dimitrov; James N Atkins; Norman S Abramson; Sofia D Merajver; Edward Romond; Carl G Kardinal; HR Shibata; Richard G Margolese; W B Farrar
Tamoxifen and chemotherapy for axillary node-negative, estrogen receptor-negative breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-23.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(4):931-42.
1999: Norman Wolmark; H Rockette; Eleftherios P Mamounas; J Jones; Samuel Wieand; D Lawrence Wickerham; Harry D Bear; James N Atkins; NV Dimitrov; Andrew G. Glass; Edwin R Fisher; Bernard Fisher
Clinical trial to assess the relative efficacy of fluorouracil and leucovorin, fluorouracil and levamisole, and fluorouracil, leucovorin, and levamisole in patients with Dukes' B and C carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project C-04.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(11):3553-9.
1999: Bernard Fisher; Steve Anderson; Arthur DeCillis; NV Dimitrov; James N Atkins; Louis Fehrenbacher; P H Henry; Edward Romond; Keith S Lanier; E Davila; Carl G Kardinal; L Laufman; H Irving Pierce; Norman S Abramson; A M Keller; J T Hamm; D Lawrence Wickerham; Mirsada Begovic; Elizabeth Tan-Chiu; W Tian; Norman Wolmark
Further evaluation of intensified and increased total dose of cyclophosphamide for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-25.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(11):3374-88.
1999: Eleftherios P Mamounas; Samuel Wieand; Norman Wolmark; Harry D Bear; James N Atkins; K Song; J Jones; H Rockette
Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B versus Dukes' C colon cancer: results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04)
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(5):1349-55.
1997: Bernard Fisher; James J Dignam; Norman Wolmark; Arthur DeCillis; B Emir; D Lawrence Wickerham; John Bryant; NV Dimitrov; Norman S Abramson; James N Atkins; HR Shibata; L Deschenes; Richard G Margolese
Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer.
Journal of the National Cancer Institute 1997;89(22):1673-82.
1997: Bernard Fisher; Steve Anderson; D Lawrence Wickerham; Arthur DeCillis; NV Dimitrov; Eleftherios P Mamounas; Norman Wolmark; R Pugh; James N Atkins; Frederick J Meyers; Norman S Abramson; J Wolter; R S Bornstein; L Levy; Edward Romond; V Caggiano; M Grimaldi; P Jochimsen; P Deckers
Increased intensification and total dose of cyclophosphamide in a doxorubicin-cyclophosphamide regimen for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-22.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1997;15(5):1858-69.
1996: Bernard Fisher; James J Dignam; Eleftherios P Mamounas; Joseph P Costantino; D Lawrence Wickerham; C Redmond; Norman Wolmark; NV Dimitrov; D M Bowman; Andrew G. Glass; James N Atkins; Norman S Abramson; C M Sutherland; B S Aron; Richard G Margolese
Sequential methotrexate and fluorouracil for the treatment of node-negative breast cancer patients with estrogen receptor-negative tumors: eight-year results from National Surgical Adjuvant Breast and Bowel Project (NSABP) B-13 and first report of findings from NSABP B-19 comparing methotrexate and fluorouracil with conventional cyclophosphamide, methotrexate, and fluorouracil.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1996;14(7):1982-92.